Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib

MeSH terms

• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use
• Antiprotozoal Agents / therapeutic use
• Bone Marrow Cells / drug effects
• Bone Marrow Cells / immunology
• Bone Marrow Cells / parasitology
• Bone Marrow Cells / pathology
• Boronic Acids / adverse effects
• Boronic Acids / therapeutic use*
• Bortezomib
• Drug Resistance, Neoplasm*
• Humans
• Immunosuppressive Agents / adverse effects
• Immunosuppressive Agents / therapeutic use*
• Italy
• Leishmania donovani / drug effects
• Leishmania donovani / isolation & purification
• Leishmaniasis, Visceral / complications
• Leishmaniasis, Visceral / drug therapy
• Leishmaniasis, Visceral / immunology*
• Leishmaniasis, Visceral / parasitology
• Male
• Middle Aged
• Multiple Myeloma / complications
• Multiple Myeloma / drug therapy*
• Multiple Myeloma / immunology*
• Opportunistic Infections / complications
• Opportunistic Infections / drug therapy
• Opportunistic Infections / immunology*
• Opportunistic Infections / parasitology
• Proteasome Inhibitors / adverse effects
• Proteasome Inhibitors / therapeutic use
• Pyrazines / adverse effects
• Pyrazines / therapeutic use*
• Treatment Outcome